A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Status:
Not yet recruiting
Trial end date:
2024-12-10
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety and tolerability of subcutaneous (SC) AMG 701 in participants
with relapsed or refractory multiple myeloma (RRMM) to determine the maximum tolerated dose
(MTD) or recommended phase 2 dose (RP2D)